Ting Wu

Shanghai Jiao Tong University, Shanghai, Shanghai Shi, China

Are you Ting Wu?

Claim your profile

Publications (50)248.85 Total impact

  • Shu Chen · Feixue Wei · Ting Wu · Ningshao Xia ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis E, caused by hepatitis E virus (HEV) infection, usually leads to an acute clinical course, and is the most common diagnosis among cases of acute viral hepatitis. From 2008, there have been increasing reports of chronic HEV infection in immunocompromised patients such as organ transplant recipients. Without intervention with antiviral treatment, approximately 60% of HEV infections in organ transplant recipients evolve into chronic HEV infections. Of these chronic hepatitis E patients, 10% may develop liver fibrosis and progress to liver cirrhosis. This article reviews chronic HEV infection and treatment in organ transplant recipients.
    Bing du xue bao = Chinese journal of virology / [bian ji, Bing du xue bao bian ji wei yuan hui] 10/2015; 31(3):293-8.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The recent earthquakes in Nepal killed thousands, displaced tens of thousands, and destroyed much of the country's infrastructure. Thousands of Nepalis are living in makeshift camps, with limited or no access to clean drinking water. There is now considerable risk of infectious diseases in affected areas.
    The Lancet 07/2015; DOI:10.1016/S0140-6736(15)61110-2 · 45.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The first commercialized hepatitis E vaccine, HEV 239, has been shown to be safe and highly immunogenic, the protection as well as the vaccine-induced anti-HEV maintained for at least 4.5 years. However, the longer term persistence of the vaccine-induced anti-HEV responses is unknown. Two statistical models, the power-law model and the modified power-law model, were applied to predict the long-term antibody response of the HEV 239 vaccine. The models were fit using the anti-HEV IgG data from a modeling subpopulation of 1278 baseline seronegative vaccinees who seroconverted within one month after finishing the whole vaccination course in the phase 3 trial of HEV 239. In addition, antibody data from a validation subpopulation were used to validate the robustness of the derived models. In the vaccinees without pre-vaccination immunity, the power-law model and the modified power-law model estimated that the median duration of the detectable antibody (≥0.077WU/ml) was 8 years and 13 years, respectively. The power-law model and the modified power-law model estimated that 50% of these vaccinees will maintain detectable levels of anti-HEV IgG for 8 years and >30 years, respectively. The recombinant hepatitis E vaccine HEV 239 is predicted to provide from 8 years to near life-long persistence of anti-HEV IgG above detectable levels. Model predictions are based on conservative mathematical assumptions. (NCT01014845). Copyright © 2015. Published by Elsevier Ltd.
    Vaccine 06/2015; 33(33). DOI:10.1016/j.vaccine.2015.06.050 · 3.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to investigate the dosage, immunogenicity and safety profile of a novel human papillomavirus (HPV) types 16 and 18 bivalent vaccine produced by E. coli. This randomized, double-blinded, controlled phase 2 trial enrolled women aged 18-25 years in China. Totally 1600 eligible participants were randomized to receive 90μg, 60μg, or 30μg of the recombinant HPV 16/18 bivalent vaccine or the control hepatitis B vaccine on a 0, 1 and 6 month schedule. The designated doses are the combined micrograms of HPV16 and 18 VLPs with dose ratio of 2:1. The immunogenicity of the vaccines was assessed by measuring anti-HPV 16 and 18 neutralizing antibodies and total IgG antibodies. Safety of the vaccine was assessed. All but one of the seronegative participants who received 3 doses of the HPV vaccines seroconverted at month 7 for anti-HPV 16/18 neutralizing antibodies and IgG antibodies. For HPV 16, the geometric mean titers (GMTs) of the neutralizing antibodies were similar between the 60μg (GMT=10,548) and 90μg (GMT=12,505) HPV vaccine groups and were significantly higher than those in the 30μg (GMT=7596) group. For HPV 18, the GMTs of the neutralizing antibodies were similar among the 3 groups. The HPV vaccine was well tolerated. No vaccine-associated serious adverse events were identified. The prokaryotic-expressed HPV vaccine is safe and immunogenic in women aged 18-25 years. The 60μg dosage formulation was selected for further investigation for efficacy. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Vaccine 06/2015; 33(32). DOI:10.1016/j.vaccine.2015.06.052 · 3.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intrauterine growth restriction (IUGR) is associated with various prenatal risks and postnatal adverse outcomes. The aim of this study is to choose the most sensitive newborn anthropometric measure, which is closely associated with IUGR-related risks and outcomes, to substitute IUGR after delivery. Data were obtained from the Collaborative Perinatal Project, a multicenter prospective cohort study in the United States from 1959 to 1976. Maternal heavy smoking and severe hypertensive disorders during pregnancy, neonatal polycythemia and hypothermia, low intelligence quotient (<70) at age 7 years were chosen as IUGR-related risks and outcomes. Eight anthropometric measures at birth were tested by logistic regression model. Birth weight-to-head circumference (W/HC) had the largest odds ratio (OR) for neonatal polycythemia (OR = 1.8, 95% confidence interval [CI] = 1.5-2.0), severe hypertensive disorders (OR = 1.9, 95% CI = 1.5-2.2), and maternal heavy smoking (OR = 1.9, 95% CI = 1.7-2.1) during pregnancy. It also had the highest summary OR (9.3). Thus, W/HC may be a good measure for IUGR. © The Author(s) 2015.
    Clinical Pediatrics 04/2015; DOI:10.1177/0009922815579688 · 1.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis E virus (HEV) is a leading cause of acute hepatitis. The long-term efficacy of a hepatitis E vaccine needs to be determined. In an initial efficacy study, we randomly assigned healthy adults 16 to 65 years of age to receive three doses of either a hepatitis E vaccine (vaccine group; 56,302 participants) or a hepatitis B vaccine (control group; 56,302 participants). The vaccines were administered at 0, 1, and 6 months, and the participants were followed for 19 months. In this extended follow-up study, the treatment assignments of all participants remained double-blinded, and follow-up assessments of efficacy, immunogenicity, and safety were continued for up to 4.5 years. During the 4.5-year study period, 60 cases of hepatitis E were identified; 7 cases were confirmed in the vaccine group (0.3 cases per 10,000 person-years), and 53 cases in the control group (2.1 cases per 10,000 person-years), representing a vaccine efficacy of 86.8% (95% confidence interval, 71 to 94) in the modified intention-to-treat analysis. Of the participants who were assessed for immunogenicity and were seronegative at baseline, 87% of those who received three doses of the hepatitis E vaccine maintained antibodies against HEV for at least 4.5 years; HEV antibody titers developed in 9% in the control group. The rate of adverse events was similar in the two groups. Immunization with this hepatitis E vaccine induced antibodies against HEV and provided protection against hepatitis E for up to 4.5 years. (Funded by the Chinese Ministry of Science and Technology and others; ClinicalTrials.gov number, NCT01014845.).
    New England Journal of Medicine 03/2015; 372(10):914-22. DOI:10.1056/NEJMoa1406011 · 55.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis E virus (HEV) infection is one of the main causes of acute hepatitis worldwide. A recombinant hepatitis E vaccine, HEV 239, has been licensed in China for immunizing adults of 16 year old and above. The vaccine antigen contains pORF2 aa 368 - 606 of the HEV genotype 1 expressed in E. coli. The quality of the vaccine is controlled through a combination of biophysical, biochemical and immunochemical methods. The vaccine is well tolerated in adults. The efficacy of the HEV 239 vaccine against symptomatic and asymptomatic infection had been proven to be high during a Phase III clinical trial and long-term follow up. The safety and efficacy of HEV 239 vaccine in certain high-risk populations remains to be further investigated.
    Human Vaccines and Immunotherapeutics 02/2015; 11(4). DOI:10.1080/21645515.2015.1008870 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple phenolic compounds in the extract of Erigeron breviscapus synergistically contribute to the neurovascular protective effects. We conducted a phase I and pharmacokinetic study with the phenolic compound-enriched product extracted from Erigeron breviscapus, Erigerontis hydroxybenzenes injection (EHI), in healthy Chinese volunteers. A randomized, open-label, single-center, double-arm, dose-escalation study of EHI was conducted. The tolerability of intravenously EHI administrated in single- or multiple-dose (once daily for 7 days) was studied in 40 healthy Chinese volunteers and the pharmacokinetics of EHI was studied in additional 10 volunteers. The tolerated dose of intravenous infusion of EHI in healthy Chinese volunteers was 6 vials (equivalent to 90 mg bioactive phenolic compounds). The main limitations to dose escalation of EHI were transit changes in electrocardiogram and mild, transit increase in alanine aminotransferase. After intravenous administration of EHI, the average systemic clearance of multiple phenolic compounds of scutellarin, 1,3-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 3,4-dicaffeoylquinic acid were 131, 29, 262, 112 L/h for male volunteers and 202, 28, 252, 117 L/h for female volunteers. The intervention of intravenous infusion of EHI in healthy Chinese volunteers was generally tolerated. The findings from this study provide data on the tolerability and pharmacokinetics of the extract from Erigeron breviscapus and support further trials. Copyright © 2015 Elsevier GmbH. All rights reserved.
    Phytomedicine: international journal of phytotherapy and phytopharmacology 01/2015; 22(2). DOI:10.1016/j.phymed.2014.11.014 · 3.13 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis E virus (HEV) is a serious public health problem. Commonly used tests specific for current HEV infection include the detection of anti-HEV IgM and HEV RNA. Here, we report an improved enzyme-linked immunosorbent assay (ELISA) method for HEV antigen detection with a linear range equivalent to 6.3×10(3)-9.2×10(5) RNA copies per mL; mAb 12F12, one high ability mAb to bind HEV virus was selected as the capture antibody from a panel of 95 mAbs. The positive period of HEV antigenemia in infected monkeys using this test was, on average, 3 weeks longer than previously reported and covered the majority of the acute phase. The positive rates of IgM, RNA and new antigen detection from the first sera collected from 16 confirmed acute hepatitis E patients were 81% (13/16), 81% (13/16) and 100% (16/16), respectively. In three patients, initial serum specimens that tested negative for IgM despite presence of symptoms of acute hepatitis and ALT elevation, were positive for HEV antigen as well as HEV RNA. In contrast, the sera of the three RNA-negative patients were antigen-positive (and IgM positive), possibly due to the degradation of HEV nucleic acids. Our results suggest that this new antigen detection method has acceptable concordance with RNA detection and could serve as an important tool for the diagnosis of acute hepatitis E. Copyright © 2014, American Society for Microbiology. All Rights Reserved.
    Journal of Clinical Microbiology 12/2014; 53(3). DOI:10.1128/JCM.01853-14 · 3.99 Impact Factor
  • Ting Wu · Hao Bai · Ping Li · Xiao‐Wei Shi ·
    [Show abstract] [Hide abstract]
    ABSTRACT: An extremely simple and compact planar monopole ultrawideband (UWB) slot antenna with dual band-notched characteristics is proposed. The antenna is composed of a circular radiation patch, a microstrip-fed line, and a partial ground. By etching an arc-shaped slot on the radiation patch and a C-like slot on the feed line, dual notched frequency bands at 3.3–3.7 GHz for WiMAX and 5.15–5.825 GHz for WLAN are achieved. And, the two notched bands can be adjusted independently by varying the length of the slots. Moreover, the band-notched characteristics can be reconfigurable by shorting the corresponding slots. So, the antenna is capable of operating in one of multiple modes which makes it an excellent candidate for UWB applications. Meanwhile, experimental results indicate that the antenna has an available impendence bandwidth from 2.9 to 11 GHz which covers the UWB frequency band, and nearly omnidirectional patterns, stable gains, small group delay in operating band except rejected bands. © 2014 Wiley Periodicals, Inc. Int J RF and Microwave CAE, 2014.
    International Journal of RF and Microwave Computer-Aided Engineering 11/2014; 24(6). DOI:10.1002/mmce.20815 · 0.85 Impact Factor
  • Source

  • Source

  • [Show abstract] [Hide abstract]
    ABSTRACT: To establish a LC-MS/MS method for quantification of chlorogenic acid, caffeic acid, 3,4-DCQA, ferulic acid and cinnamic acid in rats plasma and study its pharmacokinetics after administration of Mailuoning injection at a single dose to rats. Plasma samples were acidified with hydrochloric acid and extracted with ethyl acetate. The analytes were determined by LC-MS-MS using a ZOBAX SB C18 column with a mobile phase of methanol-water (containing 2 mmol x L(-1) ammonium acetic) (60:40)at a flow rate of 0.5 mL x min(-1) and detected using ESI with negative ionization mode. Ions monitored in the multiple reaction monitoring (MRM) mode were m/z 353.1/191.0 [M-H]- for chlorogenic acid, m/z 178.9/134.9 [M-H]- for caffeic acid, m/z 515.2/353.0 [M-H]-for 3,4-DCQA, m/z 193.0/133.9 [M-H]-for ferulic acid, m/z 146.9/102.9 [M-H]- for cinnamic acid and m/z 246.0/125.8 [M-H]- for tinidazole (IS). After administration of Mailuoning injection at a single dose to eight Sprague-Dawley rats, the concentrations of chlorogenic acid, caffeic acid, 3,4-DCQA, ferulic acid and cinnamic acid in plasma were determined by LC-MS/MS method. The main pharmacokinetics parameters of measured data were caluculated by using DASver 1.0 software. The linear concentration ranges of the calibration curves for chlorogenic acid, caffeic acid, 3,4-DCQA and cinnamic acid were 2.006-1,027 microg x L(-1) (r = 0.999 6), 1.953-1,000 microg x L(-1) (r = 0.999 7), 28.51-1.459 x 10(4) microg x L(-1) (r = 0.998 9), 1.836-940.0, g x L(-1) (r = 0.997 7) and 4.780-2,447 microg x L(-1) (r = 0.998 6) respectively. The inner and inter-days relative standard deviations were both less than 5.0%, indicating legitimate precise and accuracy to the requirement of biological sample analysis. For chlorogenic acid, the pharmacokinetic parameter t1/2, AUC0-t, and CL were (49.78 +/- 12.81) min, (123.55 +/- 14.82) mg x min x L(-1) and (0.004 3 +/- 0.000 5) L x min(-1), respectively. For caffeic acid, the pharmacokinetic parameter t1/2, AUC0-t, and CL were (36.65 +/- 10.59) min, (91.67 +/- 11.77) mg x min L(-1) and (0.005 7 +/- 0.000 7) L x min(-1), respectively. For 3,4-DCQA, the pharmacokinetic parameter t1/2, AUC0-t, and CL were (50.08 +/- 13.78) min, (278.34 +/- 31.82) mg x min x L-1 and (0.001 6 +/- 0.000 2) L x min(-1), respectively. For ferulic acid, the pharmacokinetic parameter t1/2, AUC0-t, and CL were (51.39 +/- 15.52) min, (34.72 +/- 4.67) mg x min x L(-1) and (0.000 4 +/- 0.0001) L x min(-1), respectively. For cinnamic acid, the pharmacokinetic parameter t1/2, AUCo-t, and CL were (74.42 +/- 18.32) min, (34.63 +/- 4.82) mg x min x L(-1) and (0.007 7 +/- 0.001 1) L x min-', respectively. The assay method is proved to be sensitive, accurate and convenient. It can be applied to the pharmacokinetic study of chlorogenic acid, caffeic acid, 3,4-DCQA, ferulic acid and cinnamic acid.
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 05/2014; 39(10):1928-32.
  • Source

  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Placental morphological and histopathological measures can be numerous and it is very time-consuming to collect all the information. When planning a large birth cohort study, researchers often face the dilemma as to whether and what information to collect in a placenta. The aim of this study was (1) to systematically select placental measures that have significant clinical implications, and (2) to assess the accuracy of these measures. Methods We used placental pathology information from the Collaborative Perinatal Project (CPP), in which 45,785 births had comprehensive information on placental morphology and pathology. We chose 20 major childhood diseases as outcomes. The statistical method of LASSO (least absolute shrinkage and selection operator) was used to select important placental measures that would have better predictability for outcomes. Results LASSO selected 81 measures as candidates. After having consulted placental pathologists, we further narrowed down to the 38 and 23 most important measures to form two shortened evaluation systems that could be used in clinical practice and research. The sensitivity and specificity of these measures for composite child diseases were 68% and 34%, respectively, for the 38 measures and 48% and 53%, respectively, for the 23 measures. Conclusions We presented a potentially useful system for pathological characterization of the placenta. The use of these relatively simple and accessible characteristics as biomarkers may be considered in large birth cohort studies.
    Placenta 03/2014; 35(3). DOI:10.1016/j.placenta.2014.01.006 · 2.71 Impact Factor
  • Ting Wu · Jun Zhang · Ningshao Xia ·

    Science China. Life sciences 02/2014; 57(5). DOI:10.1007/s11427-014-4623-4 · 1.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HEPATITIS E IS CAUSED BY TWO VIRAL GENOTYPE GROUPS: human types and zoonotic types. Current understanding of the epidemiology of the zoonotic hepatitis E disease is founded largely on hospital-based studies. The epidemiology of hepatitis E was investigated in a community-based surveillance study conducted over one year in a rural city in eastern China with a registered population of 400,162. The seroprevalence of hepatitis E in the cohort was 38%. The incidence of hepatitis E was 2.8/10,000 person-years. Totally 93.5% of the infections were attributed to genotype 4 and the rest, to genotype 1. Hepatitis E accounted for 28.4% (102/359) of the acute hepatitis cases and 68.9% (102/148) of the acute viral hepatitis cases in this area of China. The disease occurred sporadically with a higher prevalence during the cold season and in men, with the male-to-female ratio of 3∶1. Additionally, the incidence of hepatitis E increased with age. Hepatitis B virus carriers have an increased risk of contracting hepatitis E than the general population (OR = 2.5, 95%CI 1.5-4.2). Pre-existing immunity to hepatitis E lowered the risk (relative risk = 0.34, 95% CI 0.21-0.55) and reduced the severity of the disease. Hepatitis E in the rural population of China is essentially that of a zoonosis due to the genotype 4 virus, the epidemiology of which is similar to that due to the other zoonotic genotype 3 virus.
    PLoS ONE 01/2014; 9(1):e87154. DOI:10.1371/journal.pone.0087154 · 3.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A pseudovirion-based neutralisation assay has been considered the gold standard for measuring specific antibody responses against human papillomavirus (HPV). However, this assay is labor intensive and therefore very difficult to implement in large-scale studies. Previous studies have evaluated the agreement between virus-like particle (VLP)-based ELISA and pseudovirion-based neutralisation assays for measuring HPV vaccine-induced antibodies. However, the concordance of these assays to detect antibodies induced by natural infection has not yet been fully elucidated. In this study, the results of an Escherichia coli (E. coli)-expressed VLP-based ELISA were found to be highly concordant with those of a baculovirus-expressed VLP-based ELISA, as determined by assessing 90 human serum samples containing different levels of antibodies for HPV-16 and/or HPV-18. The correlation coefficients of the assay results were high (r = 0.98 and 0.97 for HPV-16 and HPV-18, respectively). The results of the E. coli expressed VLP-based ELISA correlated well with those of the pseudovirion-based neutralisation assay when testing 1020 post-vaccination human sera collected one month after the final vaccination with the E. coli expressed VLP-based bivalent HPV vaccine (r = 0.83 and 0.81 for HPV-16 and HPV-18). The agreement and correlation were moderate (kappa<0.3 for both HPV types 16 and 18, r = 0.59 and 0.68 for HPV-16 and HPV-18, respectively) when assessing 1600 serum samples from unvaccinated women of age 18-25 years. In conclusion, the VLP-based ELISA is an acceptable surrogate for the neutralizing antibody assay in measuring vaccine responses. However, the use of the VLP-based ELISA in epidemiological studies should be carefully considered.
    Human Vaccines & Immunotherapeutics 01/2014; 10(3). DOI:10.4161/hv.27619 · 2.37 Impact Factor
  • Source
    Hao Wang · Ping Li · Ting Wu · Xiao Wei Shi ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A compact wideband planar microstrip-fed quasi-Yagi antenna is presented. Through optimizing the structure of the C-shape reflector, a broadband impedance bandwidth of 75.3% (1.83 ∼ 4.04 GHz) for return loss less than −10 dB and a gain of 3.83 ∼ 8.48 dBi are obtained. Simulation based on HFSS and measurement results are provided and discussed. The agreements between the simulation and measurement results indicate that the antenna is suitable for wireless communication applications and phased arrays. © 2014 Wiley Periodicals, Inc. Microwave Opt Technol Lett 56:241–244, 2014
    Microwave and Optical Technology Letters 01/2014; 56(1). DOI:10.1002/mop.28025 · 0.57 Impact Factor
  • Ting Wu · Xiao-Wei Shi · Ping Li · Hao Bai ·
    [Show abstract] [Hide abstract]
    ABSTRACT: A novel and compact tri-band microstrip-fed monopole antenna with dual-polarisation characteristics for wireless local area network (WLAN) and worldwide interoperability for microwave access (WiMAX) applications is proposed. The antenna is composed of a partial ground and a Y-shaped radiating patch that consists of two unequal monopole arms and a modified circle monopole. The antenna is able to generate three separate impedance bandwidths to cover the frequency bands of the WLAN (2.4-2.484 and 5.8 GHz) and the WiMAX (3.4-3.7 GHz). In addition, the antenna is circularly polarised in both the WLAN bands. Furthermore, the antenna structure is extremely simple, durable and occupies small space, making it suitable for practical applications.
    Electronics Letters 12/2013; 49(25):1597-1598. DOI:10.1049/el.2013.3230 · 0.93 Impact Factor

Publication Stats

505 Citations
248.85 Total Impact Points


  • 2013-2015
    • Shanghai Jiao Tong University
      • Shanghai Key Laboratories of Children’s Environmental Health
      Shanghai, Shanghai Shi, China
  • 2003-2015
    • Xiamen University
      • • National Institute of Diagnostics and Vaccine Development in Infectious Diseases
      • • School of Life Sciences
      • • Key Laboratory of the Ministry of Education For Cell Biology and Tumor Cell Engineering
      Amoy, Fujian, China
  • 2013-2014
    • Xidian University
      Ch’ang-an, Shaanxi, China
  • 2010-2012
    • Nanjing University of Traditional Chinese Medicine
      Nan-ching, Jiangsu Sheng, China